Professor and Chair University of Texas Health Science Center at Houston McGovern Medical School
Join us as we reflect on the 15 years of clinical and scientific advancements following the first FDA approval of botulinum toxin for upper limb spasticity in 2010. This symposium will highlight its impact on patient care and explore future opportunities to optimize outcomes for patients living with spasticity.
